Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UARK 2008-03 Phase II Trial for Multiple Myeloma
NCT00871013Phase 2Active, not recruiting
- Sponsor
- University of Arkansas
- Start
- Mar 2009
- Primary completion
- Dec 2027
- Modality
- Modified Peptides, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan, bortezomib, thalidomide, dexamethasone, Cisplatin micelle injection (HA132) in multiple myeloma (MM), sponsored by University of Arkansas. Started Mar 2009; status: active, not recruiting.
02
Drugs
melphalanbortezomibthalidomidedexamethasoneCisplatin micelle injection (HA132)
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00871013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871013.